XOMA transitioned from a traditional biopharmaceutical developer to a specialized biotechnology royalty aggregator in July 2024. The company boasts an expansive and continuously growing portfolio of over 120 assets, with extensive diversification serving as a key strength in mitigating the inherent risks of biotech investments. Management continues to add to the diversified portfolio through disciplined capital deployment and creative financial structures.
Cyborg Score Rationale
The company has demonstrated a return to profitability with earnings of $0.82 per share over the last twelve months and impressive revenue growth of 118.02%, while maintaining a strong current ratio of 3.91. The business model provides predictable cash flows from royalties, though success depends on partner drug development outcomes.
Top Insights
Acquired 120+ therapeutic assets including Turnstone Biologics, HilleVax, LAVA Therapeutics, and Generation Bio, signaling aggressive portfolio expansion strategy
First-half 2025 generated $29.6M in partner cash including $16.0M in royalty payments from commercial sales, demonstrating revenue traction
Strategic acquisitions of entire biotech companies enable acquisition of partnered assets and clinical candidates with existing pharma relationships
Business model provides non-dilutive funding alternative to traditional venture capital and equity dilution
Venture Capital Funding — Traditional alternative capital source for biotech companies
Strategic Partnerships — Direct funding and licensing arrangements with biotech partners
Recent Developments
(December 2025) Entered into agreement to acquire Generation Bio for $4.2913 per share, expanding portfolio with cell-targeted lipid nanoparticle delivery platform and Moderna collaboration rights
(November 2025) Completed acquisitions of Turnstone Biologics and HilleVax, announced acquisition of Mural Oncology
(August 2025) Acquired mezagitamab royalty and milestone rights from BioInvent International and acquired LAVA Therapeutics
Open the full interactive XOMA Royalty Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.